



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Confirmation No.: 1733

Isa GOKCE et al.

Attorney Docket No.: P69705US0

Serial No. 10/501,071

Group Art Unit: 1653

Filed: February 14, 2005

Examiner: Robert B. MONDESI

For: FUSION PROTEINS

**AMENDMENT UNDER 37 C.F.R. 1.111**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Official Action mailed October 4, 2006, please amend the above-identified application as follows:

**Amendments to the Sequence Listing** begin on page 2 of this paper.

**Amendments to the Specification** begin on page 3 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 6 of this paper.

**Remarks** begin on page 9 of this paper.

An **Appendix** including amended Sequence Listings in CRF and paper copy is attached following page 16 of this paper.

**Amendments to the Sequence Listings:**

Please replace the Sequence Listings previously submitted with the currently submitted Sequence Listings in both computer readable form submitted in a 3.5 inch diskette and paper copy. In the amended Sequence Listing, a new SEQ ID NO: 62 has been added to specify the sequence of BCL-XL. This sequence has been obtained from SWISSPROT Accession No. B47537, which is disclosed on page 4, lines 29-30 of the specification.

According to the requirement of 37 CFR 1.821(f), Applicant hereby states that the information recorded in computer readable form is identical to the written listing of the paper copy currently submitted. In addition, Applicant hereby states that the submission, filed in accordance with 37 CFR 1.821(g), herein does not include new matter.